Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pitts

Showing results (251-260 of 268) with videos related to

Pageof 27
Sort By:
The Journal of Clinical Endocrinology and Metabolism|September 13, 2019
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor MicroenvironmentJulie Lang, Anna Capasso, Kimberly R Jordan, et al.
Molecular Cancer Therapeutics|September 7, 2019
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast CancerAnna Capasso, Stacey M Bagby, Kyrie L Dailey, et al.
Nature Neuroscience|June 8, 2023
Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer's diseaseZhuoran Yin, Shawn Herron, Sebastian Silveira, et al.
Frontiers in Oncology|November 24, 2022
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse modelsJulie Lang, Alexis D Leal, Juan A Marín-Jiménez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2019
Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation CombinationShelby Lennon, Ayman Oweida, Dallin Milner, et al.
Cancer Research|July 26, 2018
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal CancerAnuradha Krishnamurthy, Arvind Dasari, Anne M Noonan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerAnna Spreafico, John J Tentler, Todd M Pitts, et al.
Molecular Cancer Therapeutics|December 30, 2021
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid TumorsJennifer R Diamond, Todd M Pitts, Dana Ungermannova, et al.
International Journal of Cancer|July 9, 2015
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancerJohn J Arcaroli, W M Tai, Ryan McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2024
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal CancerRobert W Lentz, Tyler J Friedrich, Patrick J Blatchford, et al.
Pageof 27

Showing results (251-260 of 268) with videos related to

Sort By:
Pageof 27
The Journal of Clinical Endocrinology and Metabolism|September 13, 2019
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor MicroenvironmentJulie Lang, Anna Capasso, Kimberly R Jordan, et al.
Molecular Cancer Therapeutics|September 7, 2019
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast CancerAnna Capasso, Stacey M Bagby, Kyrie L Dailey, et al.
Nature Neuroscience|June 8, 2023
Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer's diseaseZhuoran Yin, Shawn Herron, Sebastian Silveira, et al.
Frontiers in Oncology|November 24, 2022
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse modelsJulie Lang, Alexis D Leal, Juan A Marín-Jiménez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2019
Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation CombinationShelby Lennon, Ayman Oweida, Dallin Milner, et al.
Cancer Research|July 26, 2018
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal CancerAnuradha Krishnamurthy, Arvind Dasari, Anne M Noonan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerAnna Spreafico, John J Tentler, Todd M Pitts, et al.
Molecular Cancer Therapeutics|December 30, 2021
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid TumorsJennifer R Diamond, Todd M Pitts, Dana Ungermannova, et al.
International Journal of Cancer|July 9, 2015
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancerJohn J Arcaroli, W M Tai, Ryan McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2024
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal CancerRobert W Lentz, Tyler J Friedrich, Patrick J Blatchford, et al.
Pageof 27